TLC immunostaining for glycolipids is a technique where glycolipids are separated by thin layer chromatography (TLC) and detected using specific antibodies. Samples containing glycolipids are applied to a TLC plate, separated based on their molecular mobility, treated with antibodies specific to the separated glycolipids, and stained with enzyme-labeled secondary antibodies to identify the target glycolipids. The key advantages of TLC immunostaining include minimal sample pretreatment and the ability to simultaneously separate and detect multiple glycolipids, thus making it suitable even for small sample volumes. This method is faster and simpler compared to other techniques for analyzing complex glycolipids.
Reagents and Materials
Glycolipid Solution: Dissolved at 0.1 mg/mL in methanol
Flow cytometry (FCM) for detecting cell surface involves the use of specific antibodies or lectins to bind glycolipids, with fluorescence intensity measured on a cell-by-cell basis. This technique provides highly sensitive analysis of glycolipid expression on the cell surface. Other glycolipid detection methods include thin- layer chromatography (TLC), and mass spectrometry (MS). FCM can analyze thousands of cells per second, providing a unique advantage by enabling the comparison of glycolipid expression patterns in individual cells, thus offering a perspective different from MS. While MS excels in compositional analysis and structural identification, FCM is particularly useful for pathological analysis and biomarker discovery based on cell-specific glycolipid diversity.
Add Anti-αGal Polyclonal Antibody R-PE Conjugate or Anti-NeuGc Polyclonal Antibody R-PE Conjugate, along with isotype control to a final concentration of 10 μg/mL each and incubate on ice for 30 minutes.
Wash 3 times with PBS containing 1% FBS.
Measure peripheral blood mononuclear cells using flow cytometry.
Specific Detection of Chondroitin Sulfate-A (CS-A) and Chondroitin Sulfate-D (CS-D) Using Anti-Chondroitin Sulfate Antibodies
The extracellular matrix (ECM) is an essential component in higher organisms, facilitating the formation of cells, tissues, and organs, as well as regulating cell-cell junctions and functions. The ECM also significantly influences various biological processes, including development, aging, inflammation, wound healing, and immunity. Glycosaminoglycans (GAGs), such as chondroitin sulfate, hyaluronic acid, and keratan sulfate, are major components of the ECM and play vital roles in these processes. However, analyzing GAGs, particularly in situ within cells and tissues, is challenging. As a result, antibodies are valuable tools for their detection.
Reagents and Materials
BSA-conjugated Chondroitin Sulfate Antibodies (CS-A: derived from whale cartilage, CS-D: derived from shark cartilage, CS-E: derived from squid cartilage)
Coating: Add 100 μL of each BSA-conjugated CS (diluted to 1 μg/mL in coating buffer) to separate wells of a high-binding ELISA plate and incubate overnight at 4 °C.
Blocking: After washing (*), add 150 μL/well of blocking buffer to wells and incubate at room temperature for 2 hours.
Primary Antibody: After washing (*), add 100 μL of anti-CS antibodies (diluted with blocking buffer) to the appropriate wells and incubate at room temperature for 30 minutes.
Secondary Antibody: After washing (*), add 100 μL/well of HRP-conjugated Anti-Mouse IgG+M Antibody (diluted with blocking buffer) and incubate at room temperature for 30 minutes.
Chromogenic Reaction: After washing (*), add 100 μL/ well of HRP Chromogenic Substrate Solution and incubate at room temperature for 30 minutes.
Measurement: Add 100 μL/well of Stop Solution and measure the absorbance at 450 nm (Ref. 630 nm) with a plate reader.
*Between each step, wash plates 3 times (twice after coating) with 200 μL/well of wash buffer.
Structural characterization of the epitopes of the monoclonal antibodies 473HD, CS-56,and MO-225 specific for chondroitin sulfate D-type using the oligosaccharide library
Anti-Chondroitin Sulfate A Monoclonal Antibody (LY111)
Occurrence of collagen and proteoglycan forms of type IX collagen in chick embryo cartilage. Production and characterization of a collagen form-specific antibody
Structural determination of novel sulfated octasaccharides isolated from chondroitin sulfate of shark cartilage and their application for characterizing monoclonal antibody epitopes
Detection of Antibody Glycans (Detection of Non-Human Glycans of Therapeutic Antibodies)
The glycan structure of antibody and biopharmaceutical drugs has a significant impact on drug efficacy and safety. Glycans are involved in antibody stability, blood half-life, and immunoreactivity. In particular, glycosylation of the Fc region affects antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Since non-human animal cell lines are also used in the production of biopharmaceuticals, the addition of non-human glycans, especially those containing α-1,3-galactose and N-glycolylneuraminic acid (Neu5Gc), is undeniable. These glycans can be recognized by the human immune system and may increase the risk of immune or allergic reactions. For these reasons, the detection of non-human-type glycans has become important. The detection applications of these non-human glycans are presented here.
Coating of antibody: Coat the high conjugate ELISA plate with 5 μg/mL, 100 μL of anti-human Fc antibody for 2 hours at room temperature or overnight at 4°C. Then incubate the plate for 2 hours at room temperature or overnight at 4°C.
Blocking: Add 150 μL of blocking solution to each well and block overnight at room temperature for 2 hours or overnight at 4°C.
After washing the wells, dilute the test sample (cetuximab) to each concentration (0-100 ng) in the blocking solution, apply to the wells, and react for 1 hour at room temperature.
After washing the wells, add 100 μL of detection antibody (Anti-αGal Chicken Polyclonal Antibody HRP Conjugate) diluted 2000-fold to each well and react for 1 hour at room temperature.
After washing the wells, add 100 μL of HRP chromogenic substrate solution and allow to react for 30 minutes.
Add 100 μL of reaction stop solution and measure with a plate reader at 450 nm (Ref. 630 nm).
Wash the plate three times with 200 μL of washing buffer, discarding the reaction solution from the well.
Figure. Detection of non-human glycans (αGal) present in the therapeutic antibody in a dose-dependent manner in the range of 10-100 ng/mL by using sandwich ELISA
Other Examples: Detection of αGal Epitope of Therapeutic Antibodies Cetuximab by Immunochromatography Using Anti-αGal Polyclonal Antibody
Immunochromatography is a simple and rapid method that requires only a drop of specimen and provides results within 15 minutes. If both the test and control lines are chromogenic, the result is positive; if only the control line is chromogenic, the result is negative.
Schematic diagram of the immunochromatography assay
This research is partially supported by the developing key technologies for discovering and manufacturing pharmaceuticals used for next-generation treatments and diagnoses both from the Ministry of Economy, Trade and Industry, Japan (METI) and from Japan Agency for Medical Research and Development (AMED). This research was supported by AMED under Grant Number JP20ae0101057.
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.